Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Bolun Jiang

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5104082571. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2020: 6 papers · 2021: 3 papers · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 11

  1. Targeted inhibition of CHKα and mTOR in models of pancreatic ductal adenocarcinoma: A novel regimen for metastasis. First author DOI 10.1016/j.canlet.2024.217280↗
  2. FGFR3 Nuclear Translocation Contributes to Proliferative Potential and Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002056↗
  3. Elevated TIAM2 expression promotes tumor progression and is associated with unfavorable prognosis in pancreatic cancer. Co-author DOI 10.1080/00365521.2020.1853806↗
  4. Expression and Prognostic Value of Small Mothers Against Decapentaplegic 7, Matrix Metalloproteinase 2, and Matrix Metalloproteinase 9 in Resectable Pancreatic… Co-author DOI 10.1097/mpa.0000000000001892↗
  5. Clinicopathological and prognostic significance of ubiquitin-specific peptidase 15 and its relationship with transforming growth factor-β receptors in patients… Co-author DOI 10.1111/jgh.15244↗
  6. Photodynamic therapy of pancreatic cancer: Where have we come from and where are we going? Co-author DOI 10.1016/j.pdpdt.2020.101876↗
  7. Ubiquitin-specific protease 4 predicts an unfavorable prognosis and promotes malignant behaviors in vitro in pancreatic cancer. Co-author DOI 10.1016/j.yexcr.2020.112317↗
  8. Research progress on long non-coding RNAs and their roles as potential biomarkers for diagnosis and prognosis in pancreatic cancer. Co-author DOI 10.1186/s12935-020-01550-y↗
  9. Transducin-Like Enhancer of Split-1 Inhibits Malignant Behaviors in vitro and Predicts a Better Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2020.00576↗
  10. Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review. Co-author DOI 10.3389/fonc.2020.01466↗
  11. Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides? Co-author DOI 10.3389/fonc.2020.576399↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Li Zhou · 11 shared papers, 2020–2024 · strength 1.50
  2. Jun Lü · 10 shared papers, 2020–2022 · strength 1.30
  3. Junchao Guo · 7 shared papers, 2020–2024 · strength 1.00
  4. Yizhi Wang · 7 shared papers, 2020–2021 · strength 0.91
  5. Lei You · 5 shared papers, 2020–2022 · strength 0.66
  6. Zhiyong Liang · 5 shared papers, 2020–2022 · strength 0.65
  7. Yizhi Wang · 3 shared papers, 2020–2022 · strength 0.40
  8. Junchao Guo · 3 shared papers, 2020 · strength 0.37
  9. Gary Guishan Xiao · 2 shared papers, 2020–2024 · strength 0.33
  10. Wenchao Xu · 1 shared paper, 2024 · strength 0.20
  11. Guoxu Ma · 1 shared paper, 2024 · strength 0.20
  12. Qiaofei Liu · 1 shared paper, 2024 · strength 0.20
  13. Jianzhou Liu · 1 shared paper, 2024 · strength 0.20
  14. Junchao Guo · 1 shared paper, 2021 · strength 0.13
  15. Xi Zoë Zhong · 1 shared paper, 2020 · strength 0.13
  16. Yu-Pei Zhao · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.